The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort
Abstract
Background: Psoriasis is a common disease and is associated with cardiovascular diseases. Systemic anti‐inflammatory drugs may reduce risk of cardiovascular events. We therefore examined the rate of cardiovascular events, i.e. cardiovascular death, myocardial infarction and stroke, in patients with severe psoriasis treated with systemic anti‐inflammatory drugs. Methods: Individual‐level linkage of administrative registries was used to perform a longitudinal nationwide cohort study. Time‐dependent multivariable adjusted Cox regression was used to estimate hazard ratios (HR s) with 95% confidence intervals (CI s) of cardiovascular events associated with use of biological drugs, methotrexate, cyclosporine, retinoids and other antipsoriatic therapies, including topical treatments, phototherapy and climate therapy. Results: A total of 6902 patients (9662 treatment exposures) with a maximum follow‐up of 5 years were included. Incidence rates per 1000 patients‐years for cardiovascular events were 4.16, 6.28, 6.08, 18.95 and 14.63 for biological drugs, methotrexate, cyclosporine, retinoid and other therapies respectively. Relative to other therapies, methotrexate (HR 0.53; CI 0.34–0.83) was associated with reduced risk of the composite endpoint and a comparable but non‐significant protective effect was observed with biological drugs (HR 0.58; CI 0.30–1.10), whereas no protective effect was apparent with cyclosporine (HR 1.06; CI 0.26–4.27) and retinoids (HR 1.80; CI 1.03–2.96). Tumour necrosis factor inhibitors (HR 0.46; CI 0.22–0.98) were linked to reduced event rates, whereas the interleukin‐12/23 inhibitor ustekinumab (HR 1.52; CI 0.47–4.94) was not. Conclusion: Systemic anti‐inflammatory treatment with methotrexate was associated with significantly lower rates of cardiovascular events during long‐term follow‐up compared to patients treated with other antipsoriatic therapies. The treatment strategy in patients with severe psoriasis may have an impact on cardiovascular outcomes and randomized trials to evaluate the cardiovascular safety and efficacy of systemic antipsoriatic therapies are called for.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
PRODANOWICH, S., MA, F., TAYLOR, J., PEZON, C., FASIHI, T., & KIRSNER, R. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.06.017 · Cited by 384
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
Psoriasis and the Risk of Diabetes Mellitus: A Systematic Review and Meta-analysis
Armstrong, A. W., Harskamp, C. T., & Armstrong, E. J. (2013) · JAMA Dermatology · doi:10.1001/2013.jamadermatol.406 · Cited by 342
Cited by
Elmets, C. A., Leonardi, C. L., Davis, D. M. R., Gelfand, J. M., Lichten, J., Mehta, N. N., Armstrong, A. W., Connor, C., Cordoro, K. M., Elewski, B. E., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.058 · Cited by 503
Egeberg, A., Ottosen, M. B., Gniadecki, R., Broesby-Olsen, S., Dam, T. N., Bryld, L. E., Rasmussen, M. K., & Skov, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16102 · Cited by 284
Self-citationYang, Z.-S., Lin, N.-N., Li, L., & Li, Y. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8560-9 · Cited by 123
Inflammation in Coronary Microvascular Dysfunction
Sagris, M., Theofilis, P., Antonopoulos, A. S., Oikonomou, E., Paschaliori, C., Galiatsatos, N., Tsioufis, K., & Tousoulis, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413471 · Cited by 115
Shaaban, D., & Al-Mutairi, N. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2016.1254145 · Cited by 18
Metadata
- Authors
- Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L. E., Lasthein, S., Lindhardsen, J., Kristensen, S. L., Torp‐Pedersen, C., & Hansen, P. R.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2014-10-10
- Volume
- 29
- Issue
- 6
- Pages
- 1128-1134
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W1969097286
- Cited by
- 189
- References
- 7
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort. https://app.cochat.ai/papers/10.1111/jdv.12768
- The paper
- Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L. E., Lasthein, S., Lindhardsen, J., Kristensen, S. L., Torp‐Pedersen, C., & Hansen, P. R. (2015). Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.12768
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.